Therefore, in KL tumors, whether LOXL-2 is a key regulator contributing to activated FAK pathway in CAF needs to be further investigated; and (iii) TME features in subcutaneous tumor models might be distinct from that in orthotopic tumors. This evidence concerns the gene LOXL2 and neoplasm.